Method for diagnosing, preventing, and treating neurological diseases

Patent metadata

Field	Value
Publication number	US-9707207-B2
Application number	US-201113117073-A
Country	US
Kind code	B2
Filing date	May 26, 2011
Priority date	May 26, 2010
Publication date	Jul 18, 2017
Grant date	Jul 18, 2017

Abstract

The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.

First claim

What is claimed is:

1. A method of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam and a beta-lactamase inhibitor in an amount effective to treat autism in the patient, thereby treating autism, wherein the beta-lactamase inhibitor is selected from the group consisting of clavulanic acid, tazobactam, sulbactam and LK-157.

2. The method of claim 1 , wherein aztreonam and the beta-lactamase inhibitor are administered concurrently.

3. The method of claim 1 further comprising administering a probiotic and/or a probiotic group.

4. The method of claim 3 , wherein the probiotic and/or a probiotic group is selected from the group consisting of bacteria that competes with Desulfovibrio for nutrients in the intestinal tract and bacteria that inhibits growth of Desulfovibrio in the intestinal tract.

5. The method of claim 4 , wherein a probiotic and/or a probiotic group is selected from the group consisting of Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides fragilis, Bifidobacterium adolescentis group, Eubacterium aerofaciens, Clostridium ramosum, Escherichia coli, Streptococcus faecalis group, Lactobacillus spp., L. acidophilus , gram-negative anaerobes, enterococci, Bacteroides sp., Parabacteroides, Prevotella, Porphyromonas , gram-positive anaerobic cocci, Clostridium sp., Enterobacteriaceae, E. coli, L. bulgaricus, S. thermophilus, Collinsella genus, Bifidobacterium genus, Bifidobacterium longum, Bifidobacterium angulatum, Dialister invisus, Clostridium leptum, Firmicutes, Actinobacteria, Faecalibacterium, Ruminococcus, Eubacterium, Alistipes, Roseburia, Anaerofilum, Streptococcus, Turicibacter, Parabacteroides, Dorea, Veillonella, Akkermansia, Sporobacter, Ethanoligenens, Papillibacter, Holdemania, Weissella, Dialister, Pseudoramibacter, Streptococcus, Anaerovorax, Lactococcus, Leuconostoc, Ethanoligenens, Helcococcus, Alkaliphilus, Clostridium aldenense, Clostridium methylpentosum, Eubacterium ruminantium, Phascolarctobacterium faecium, Alistipes onderdonkii, Bacteroides caccae and mixtures thereof.

Assignees

• Finegold Sydney Martin
• Us Veterans Affairs

Inventors

• Finegold Sydney Martin

Classifications

• A61K35/745

  Bifidobacteria · CPC title

• A61K35/747

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

• A61K31/397 Primary

  having four-membered rings, e.g. azetidine · CPC title

• C12Q1/18

  Testing for antimicrobial activity of a material · CPC title

• A61K35/741

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title